# First experimental proof of Proton Boron Capture Therapy (PBCT) to enhance protontherapy effectiveness

## Abstract

Protontherapy is hadrontherapy’s fastest-growing modality and a pillar in the battle against cancer. Hadrontherapy’s superiority lies in its inverted depth-dose profile, hence tumour-confined irradiation. Protons, however, lack distinct radiobiological advantages over photons or electrons. Higher LET (Linear Energy Transfer) 12C-ions can overcome cancer radioresistance: DNA lesion complexity increases with LET, resulting in efficient cell killing, i.e. higher Relative Biological Effectiveness (RBE). However, economic and radiobiological issues hamper 12C-ion clinical amenability. Thus, enhancing proton RBE is desirable. To this end, we exploited the p + 11B → 3α reaction to generate high-LET alpha particles with a clinical proton beam. To maximize the reaction rate, we used sodium borocaptate (BSH) with natural boron content. Boron-Neutron Capture Therapy (BNCT) uses 10B-enriched BSH for neutron irradiation-triggered alpha particles. We recorded significantly increased cellular lethality and chromosome aberration complexity. A strategy combining protontherapy’s ballistic precision with the higher RBE promised by BNCT and 12C-ion therapy is thus demonstrated.

## Introduction

The combination of ballistic precision with an increased ability to kill cells is the radiobiological rationale currently supporting the clinical exploitation of heavier particles such as fully stripped 12C-ions18, which present some advantages over protons6,18. Not only do they ensure a better physical dose distribution, due to less lateral scattering19, but they also result more biologically effective both in vitro and in vivo as a result of their higher Linear Energy Transfer (LET)11,20,21. In fact, densely ionizing radiation tracks cause more spatio-temporally contiguous and complex lesions at the DNA level, comprising DNA double-strand breaks and damaged bases, which are highly clustered in nature22,23,24. This impairs cellular ability for correct repair25 and decreases the dependence of radiosensitization upon the presence of oxygen, desirable features for eradication of resilient, hypoxic tumors5,26. Further potential radiobiological advantages include greater RBE for killing putatively radioresistant cancer stem cells27 and counteracting cancer invasiveness28,29, albeit the latter remains controversial30. Finally, low doses of high-LET radiation appear to elicit stronger immunological responses compared to low-LET radiation16.

On the other hand, complications related to nuclear fragmentation from the primary beam, along with a partial understanding of the consequences of the exposure of normal cells to high-LET radiation, and also considering the complexity and high costs associated with a 12C treatment facility, fueled research into exploring novel strategies with the aim to achieve alternative solutions for a localized increase of proton RBE.

One of such recently proposed approaches foresees the use of gold nanoparticles as protontherapy radiosensitizers31. The ability of particle radiation to stimulate favourable immunological responses represents another attractive solution as it has become increasingly evident that proton and photon irradiation differentially modulate systemic biological responses8,17.

In this work, we experimentally test for the first time the idea theoretically proposed by Do-Kun Y et al. in32, based on the use of the p + 11B → 3α nuclear fusion reaction33,34 to enhance proton biological effectiveness exclusively in the tumour region through the generation of short-range high-LET alpha particles, thus being of potential clinical worth. Cells were irradiated with a clinical proton beam in the presence of sodium borocaptate (NA2B12H11SH or “BSH”), which is a common agent clinically used in BNCT in its 10B-enriched form to selectively deliver given boron concentrations in cancer cells35. BNCT requires thermal neutrons to trigger the reaction where two charged particles (one alpha of 1.77 MeV and one 7Li ion of 1.015 MeV) with a positive Q value of 2.792 MeV are produced36. In order to maximize the p + 11B → 3α fusion rate, we used BSH with natural occurring boron isotopic abundance (i.e. about 80% 11B and 20% 10B). We observed a significant increase in proton-induced cytogenetic effects, both in terms of cell death, assessed as loss of proliferative potential by the clonogenic assay, and of induction of DNA damage. The latter was studied by chromosome aberrations revealed by Fluorescence In Situ Hybridization (FISH) painting techniques. Specifically, the markedly higher frequency of complex-type chromosome exchanges (a typical cytogenetic signature of high-LET ionizing radiation, see ref.37, which was found among boron-treated cells compared to proton-irradiated cells in the absence of BSH, points to alpha particles generated in the nuclear fusion reaction as being responsible for the measured enhancement of proton biological effectiveness. These findings, therefore, yield important implications for an enhanced cancer protontherapy.

## Results

### Experimental approach

The proton-boron nuclear reaction considered in this work is usually formalized as p + 11B —> 3α. It has a positive Q-value (8.7 MeV) and is often referred to as “proton-boron fusion reaction” since the incident proton is completely absorbed by the 11B nucleus. This reaction has garnered interest since the 1930s33,34 because of the process ability to produce copious numbers of alpha particles in an exothermic reaction.

According to the most recent studies and interpretations, p + 11B —> 3α can be described as a two-step reaction (involving 12C and 8Be nuclei excitation) with a main resonance occurring at a 675 keV (center of mass energy) and where the maximum cross section of 1.2 barn is measured38,39. A more detailed description of the reaction is reported in Methods. The emitted alpha particles exhibit a wide energy spectrum with a predominant energy around 4 MeV40. Such a reaction has been considered very attractive for the generation of fusion energy without producing neutron-induced radioactivity41,42.

Such a nuclear reaction may be even more useful as it could play a strategic role in medical applications improving the effectiveness of protontherapy. The potential clinical use of the p-11B reaction has been thus far only investigated and validated by means of Monte Carlo simulations32,43, with preliminary experimental work on its imaging potentialities44,45 being also performed. In this paper, we experimentally implement for the first time this innovative approach in a clinical scenario by measuring the biological effects as a direct consequence of the p-11B reaction.

Besides the advantage of using a neutron-free nuclear fusion reaction, the relevance of this method stems from the fact that the p + 11B → 3α cross section becomes significantly high at relatively low incident proton energy, i.e. around the Bragg peak region. As schematically depicted in Fig. 1, a proton beam as conventionally used in protontherapy is drastically slowed down across the tumour (the Bragg peak region). Thus, most of its energy (dose) is delivered to the tumour cells. Under the assumption that a given concentration of 11B nuclei is present preferentially, but not exclusively, in the tumour, the arrival of slow protons could trigger a series of fusion events generating several alpha particles that are localized in the tumour region. In fact, most of the alpha particles generated in the proton-boron reaction have an average range in water of less than 30 μm, thus comparable with the typical cell size. Hence, even if such particles are mainly produced outside the cell cytoplasm due to sub-optimal boron uptake, the probability that they would reach the nucleus and damage the DNA remains very high. Moreover, even if a non-negligible concentration of 11B nuclei is present in the healthy tissues surrounding the tumour, the number of fusion events (i.e. generated alpha particles), would be relatively low, or completely absent, due the non-favourable incident proton energy spectrum away from the tumour region. This would lead to a more biologically effective particle dose localization, higher than the one currently achievable with conventional protontherapy, thus to a more efficient treatment in terms of an enhancement in cancer cell lethality, especially because of the clustered nature of the DNA damage, which is caused by the high-LET alpha particles emitted in the tumour region. Hence, protontherapy could acquire the benefits of an enhanced efficiency in cancer cell killing, moving close to 12C ion hadrontherapy but without the above-mentioned complications of the latter.

The ballistic advantage granted by the inverted dose-depth profile of charged particles is such that in protontherapy most of the dose is released mainly in the tumor region (upper panel), cancer cells being represented here by purple circles and damaging events by black dots (A): proton-induced damage is similar to that imparted to DNA by photons, consisting mainly of isolated lesions (middle and lower panels). If cancer cells are loaded with 11B-delivering agents (middle panel, B), as is the case with 10B-enriched compounds in BNCT, unrepairable DNA clustered lesions will be also produced by the high-LET alpha particles generated by the p-11B nuclear fusion reaction (lower panel). This in turn leads to a Dose Modifying Factor (DMF) for cancer cell killing while maintaining beneficial sparing of surrounding healthy tissues (middle panel). Furthermore, for a given clinical case, such higher DMF can potentially allow to reduce the overall dose delivered to the patient (lower total number of protons used in the number of fractions) compared to a standard treatment without the presence of 11B-delivering agents in the tumor.

### BSH enhances cancer cell death following proton-irradiation

A slight yet not statistically significant effect due to boron concentration was observed. Based upon the measured survival dose-responses, a calculated DMF of 1.46 ± 0.12 was determined at the 10% survival level (DMF10). This indicated that the presence of the boron compound conferred a radiobiological advantage at reducing cell survival compared to proton irradiation alone. At the concentrations used, BSH was not cytotoxic since the proliferative potential of unirradiated cells as given by cellular plating efficiency was not affected by the presence of BSH (Table 2). This means that the measured enhancement of proton effectiveness at cell killing was not contributed to by cytotoxicity caused by the boron-containing compound per se.

### Dependence of BSH-mediated cell killing enhancement upon proton energy

Our working hypothesis is that the nuclear fusion p + 11B → 3α (p-B) reaction results in a significant increase in proton biological effectiveness due to the short-range high-LET alpha particles it produces. Such a reaction critically depends on the incident proton energy; hence, its radiobiological effectiveness can be expected to vary along the clinical proton SOBP. To verify this hypothesis, the induction of cell killing in the presence of the boron compound at the concentration of 80 ppm 11B (Fig. 2), was investigated irradiating the cancer DU145 cell line at the beam entrance (P1 position), at the SOBP distal end (P3 position), and at the middle of the SOBP (P2) as above reported (Fig. 3).

The panel in Fig. 4 shows the clonogenic survival dose-response curves derived from the three positions along the SOBP, in the absence or presence of BSH. In line with the expected variation in cell radiosensitivity along a clinical SOBP14, proton irradiation alone resulted in a progressive increase in cell killing from P1 to P3. Interestingly, data clearly show no effect of BSH at the beam entrance. A DMF of about 1.4 was confirmed at 10% cell survival at mid-SOBP: here, fitting parameters were α = (0.309 ± 0.022) Gy−1 and β = (0.040 ± 0.006) Gy−2 for proton irradiation without BSH and α = (0.653 ± 0.018) Gy−1 in the presence of 80 ppm 11B. At the distal end of the SOBP, however, BSH appeared to be even more effective with a recorded DMF of 1.75 ± 0.13: at this position, cell killing was best described by a pure exponential for both protons alone and protons in the presence of BSH, with values for the α parameter of (0.541 ± 0.027) Gy−1 and (0.952 ± 0.053) Gy−1. These experimental results, particularly the lack of a measurable effect due to the presence of 11B at beam entrance where the incident proton energy is the highest, confirm that the enhancement of biological effectiveness is caused by the occurrence of p-B nuclear fusion events, which have a higher probability (i.e. higher cross section) at relatively low energy (MeV level) of the incoming protons, i.e. towards the end of their range.

### BSH exacerbates proton irradiation-induced chromosome aberrations and enhances complex-type exchanges

Ionizing radiation can give rise to a wide spectrum of structural chromosome aberrations or CAs49. It is long-known that CAs are closely linked to clonogenic cell death50, hence an increase in cell killing due to the alpha particles produced by the p-B reaction ought to reflect in an increase in the yield of CAs. Furthermore, complex-type exchanges, defined as those rearrangements involving at least two chromosomes and generated by at least three breaks, are an archetypical feature of high-LET exposure37,51. Therefore, quantification of the proportion of complex-type chromosome exchanges was instrumental to unveil the action of high-LET alpha particles generated by the BSH-assisted p + 11B → 3α nuclear reaction. To this end, in addition to conventional FISH labelling (which is limited to painting two pairs of homolog chromosomes) a more comprehensive investigation was also carried out employing the multicolour(m)-FISH technique, which represents the method of choice when an accurate scoring of CAs, particularly of those of complex type, is required since it allows analysis of the whole karyotype. This is exemplified by Fig. 5 showing two cells from a sample irradiated with 4Gy of protons in the presence of 80 ppm 11B. One cell is conventionally FISH-painted, presenting with chromosome rearrangements of complex nature as several portions of the painted chromosomes are aberrantly joined with aspecifically stained chromosomes (appearing blue) and with themselves. The other cell has been subjected to mFISH analysis revealing a number of aberrations that would have gone undetected confining analyses to conventional FISH scoring.

Cancer cells are known to be genetically unstable; hence, they do not lend themselves to reliable assessment of radiation-induced DNA damage. Radiation-induced chromosome rearrangements would superimpose onto an elevated confounding frequency of baseline damage. Therefore, the non-tumorigenic breast epithelial MCF-10A cell line was chosen for scoring of radiation-induced CAs.

In cells not exposed to radiation, BSH per se did not cause significantly higher genotoxic damage compared to BSH-untreated cells, in agreement with the lack of cytotoxicity as measured by clonogenic assay (Table 2). Conversely, proton irradiation resulted in a higher yield of all CA types in cells treated with BSH compared to cells irradiated with protons in the absence of BSH (Fig. 6). As expected, the overall measured frequency of CAs raised for all irradiation conditions when using mFISH because of its greater sensitivity. Moreover, the boron-mediated enhancement of chromosomal damage is slightly amplified passing from conventional FISH scoring to mFISH analysis: the yield of CAs following 2Gy of protons in combination with BSH increased from about 0.22 to 0.47 aberrations per cell compared to about 0.11 and 0.20. Furthermore, when mFISH analysis was performed, measured CA frequency values “fan out” as dose increases showing a small effect due to 11B concentration at the highest proton dose, i.e. 4Gy, with 80 ppm of 11B appearing slightly more effective than 40 ppm. The yield of CAs following x-rays was identical to that measured after exposure to protons in the absence of BSH, in line with the observed lack of a significant difference in cell killing between x-rays and protons alone also seen in DU145 cancer cells (Fig. 2).

Aberration data were fitted to a linear –quadratic function of the type Y = Y0+α*D+β*D2 where the coefficient Y0 corresponded to the baseline CA frequency as reported in Table 2. As from mFISH analysis, following irradiation in the absence of BSH, no statistically significant value for the parameter α was found, while a value of β = (0.051 ± 0.026) Gy−2 could be derived; whereas α and β were (0.154 ± 0.066) Gy−1 and (0.034 ± 0.020) Gy−2 for proton irradiation in the presence of 80 ppm of 11B. Because of the purely quadratic nature of the dose-response curve for proton irradiation in the absence of BSH, no estimate for DMFmax could be derived as this is defined as the ratio of the linear components of the linear-quadratic dose-response curve by analogy with the concept of RBE52. DMF values were calculated for two levels of damage instead, that is 20 and 40 aberrations per 100 cells. In the case of 20 aberrations per 100 cells, the calculated DMF was about 2.1, whereas a DMF value of 1.6 was obtained for the level of 40 aberrations per 100 cells.

The most interesting result, however, came from the analysis of complex-type aberration exchanges. A markedly pronounced occurrence of complex-type exchanges was found in samples treated with BSH compared to cells that had been irradiated with protons in the absence of BSH (Fig. 7). After 0.5 Gy of protons, the frequency of complex CAs ranged between 0.025 and 0.028 for BSH-treated cells as opposed to less than 0.004 in the case of cells irradiated in the absence of BSH. These values dramatically increased with dose and remained consistently higher in the case of BSH-treated cells, reaching about 0.18 and 0.08 after 4 Gy of protons in the presence or the absence of BSH, respectively. Occurrence of complex-type exchanges following x-rays is also shown for comparison (Fig. 4) and does not differ from that measured for proton irradiation alone. Analysis by m-FISH confirmed such findings revealing how at high dose (4 Gy) conventional FISH scoring tends to underestimate the occurrence of complex exchanges, at which dose, as was the case for the total yield of aberrations, m-FISH unveils a slight BSH-concentration effect masked by conventional FISH painting.

Taken together, these results strongly support the notion that the presence of BSH results in a significant dose-modifying effect on proton irradiation, increasing cell lethality and DNA damage. In particular, the profoundly enhanced yield of complex-type CAs found following proton irradiation of BSH-treated cells points to damage brought about by high-LET radiation, thus consistent with the action of the alpha particles produced by the p-B fusion reaction.

## Discussion

The first experimental evidence of a significant enhancement of proton effectiveness at causing cytogenetic damage cells, through irradiation with a clinical proton beam in the presence of a compound with natural boron isotopic content (80% of 11B + 20% of 10B), is reported. The advantage of such a new methodology consists in the use of the p-B nuclear fusion reaction, which presents a high cross section for protons with energies in the range 0.1–10 MeV, i.e. around the Bragg peak. Such a reaction produces three alpha particles with a range comparable to the typical cells’ dimensions. BSH, one of the most commonly used boron-delivering agents in BNCT, served as natural boron carrier in our study. The rationale underlying BNCT consists in cancer irradiation by thermal neutrons, which results in a highly localized and mostly lethal targeting of cancer cells because of the very short range and, hence, of the high LET of the low-energy alpha particles generated in the reaction with the 10B atoms. However, despite numerous, carefully designed and generally promising clinical trials53,54, BNCT struggles to establish itself in clinical routine, both because of the intrinsically challenging quest for ideal carriers to deliver radiobiologically effective concentrations of boron to cancer cells, and because of the limited availability of thermal neutron sources35,47. On the other hand, albeit already being a clinical reality, external beam 12C-ion hadrontherapy, which is capable of delivering very biologically effective radiation doses with extremely high precision to the tumor target, is hampered by economic and radiobiological issues as discussed in the Introduction section.

Currently, the most widespread form of cancer treatment through accelerated charged particles is represented by protontherapy, which guarantees the same ballistic precision as 12C ion beams without the added complications. The disadvantage of protontherapy is, however, a low biological effectiveness at killing cells since protons are only about as effective as photons and electrons. The approach we have successfully tested in several experimental runs could represent an enormous step towards the ability to increase the biological efficacy of proton radiotherapy and therefore expand its use towards the treatment of radioresistant tumours by coupling the already favorable spatial characteristics of protons with the capacity to trigger the proposed reaction exclusively inside the tumor. In principle, this would enable the avoidance of the intrinsic uncertainties and enormous handling complications associated with the use of neutron beams in BNCT and could lead to an increase of proton biological effectiveness towards values closer to those exhibited by 12C-ions.

The biological effects of the p-B fusion reaction were investigated by measuring clonogenic cell death and chromosome aberrations (CAs) in a prostate cancer cell line (DU145) and in a non-tumorigenic epithelial breast cell line (MCF-10A), respectively. The latter was best suited to investigate chromosomal damage as opposed to genomically unstable cancer cells.

We found that proton irradiation-induced cellular lethality was greatly enhanced by irradiating cells that had been pre-treated with BSH. In particular, our results for survival of DU145 cells following low-LET proton irradiation alone are in line with those obtained at another protontherapy facility by Polf et al.55, who studied the radiosensitizing effects of Au nanoparticles. They actually reported an enhancement of proton biological effectiveness of smaller magnitude compared to that experimentally achieved by us. Moreover, cellular survival values measured in our experiments using BSH are essentially identical to those reported by Yasui et al.48, where DU145 cells were exposed to neutrons in presence of BPA the other commonly used boron-delivering agent).

To further consolidate our experimental findings as due to the occurrence of several p-B fusion reaction events, cell survival dose response curves were obtained irradiating DU145 cells at three different positions along the proton SOBP. The results strongly argue in favour of an incident beam energy-dependent increase in proton biological effectiveness since no dose modifying effect could be measured when cells were irradiated in the presence of BSH at the beam entrance, whereas an apparent increase in effectiveness was measured as cells were irradiated at the distal end of the SOBP, in agreement with the cross section of the p-B fusion reaction, which increases with the decrease of mean proton beam energy (see Fig. 8 below).

Although measurements of 11B incorporation by cells were not performed, both drug pre-treatment times and concentrations were chosen according to available literature data for the use of the boron-carrier BSH in BNCT, according to which the optimal conditions to reach an ideal boron concentration in cells is 20 µg per grams of tissue or 109 atoms per cell58. Indeed, although 10B-enriched BSH is known for its poor permeabilization through cell membranes, its use is facilitated by a higher boron content compared to the other widely used boron-delivering compound, such as BPA. However, the alpha particles emitted via the p + 11B → 3α reaction present average energies around 4 MeV MeV, which correspond to ranges in tissues of a few tens of microns, thus ensuring a severe cellular DNA damage even if BSH is not incorporated inside the cell but sits on its membrane. Moreover, the ballistic properties of the incident proton beam, whereby proton energies drastically decrease in correspondence with the tumour volume, ensure negligible nuclear fusion events even in the worst-case scenario where the delivery agent containing 11B nuclei is also heavily present in the healthy tissues surrounding the tumour. Furthermore, the presence of 10B in the proposed method allows triggering various nuclear reactions that generate prompt γ-rays, thus being potentially useful for a simultaneous treatment-and-diagnostics approach32,43,59.

The radiobiological data reported in this work suggest that the p + 11B → 3α reaction as being responsible for the observed increase in the biological effectiveness of a clinical proton beam. However desirable, we cannot currently provide a simple analytical computation able to explain our results, for instance by correlating the biological effect with the total number of α-particles that can be expected to be generated under our experimental conditions. A possible approach could be trying to calculate the increase in the overall dose and/or LET due to such particles. The current knowledge of biological radiation action has nonetheless established that, the biological effects of low-energy high-LET radiations cannot be interpreted solely on the basis of macroscopic concepts like the absorbed dose or the average LET distributions. This is due to the intrinsically inhomogeneous nature of energy deposition events along radiation tracks, which becomes more significant with their increasing ionization density. Therefore, micro- and nano-dosimetric approaches must be taken into account to analyse the effects arising at cellular level. In addition, the role of extra-targeted phenomena, such as the bystander effect whereby cells that have not been traversed directly by radiation tracks may express cytogenetic damage, is still largely undetermined in such scenario60, thereby contributing to the overall uncertainty between the physical dose distribution at the micro or nano-dosimetric level and at the cellular one..

In conclusion, if further confirmed by both in vitro and pre-clinical investigations, our results represent an important breakthrough in cancer radiotherapy, particularly in the treatment of such disease by using accelerated proton beams since it may significantly enhance its effectiveness without foreseeable patients’ health complications and added financial costs.

## Methods

### Cell cultures

Prostate cancer cell line DU145 and the spontaneously immortalized, no-transformed human mammary epithelial MCF-10A cells (kindly donated by prof. K. Prise, School of Medicine, Dentistry and Biomedical Sciences, QUB, UK) were grown in 25-cm2 (T25) standard tissue culture flasks, routinely subcultured and maintained at 37 °C in a humidified atmosphere (95% air, 5% CO2). DU145 cells were used to assess possible enhancement by boron of proton-induced cancer cell death while chromosomal DNA damage was investigated in MCF-10A cells. DU145 cells were grown in RPMI medium supplemented with 10% fetal bovine serum and 1% antibiotics. Two media were instead needed for MCF-10A cells, one for optimal growth conditions and the other for resuspension and quenching of trypsin, as described in detail by Debnath et al.61. Two days before irradiation DU145 and MCF-10A cells were seeded in T25 flasks at 105 and 6 105 cells/flask, respectively.

### BSH preparation and treatment

A 1-g vial of sodium mercaptododecaborate or N-BSH, Na2 [B12H11SH], FW 219.87, was purchased from KATCHEM Ltd. (Czech Republic). The working concentrations of 80 and 40 ppm of 11B corresponded to 0.17 mg/ml and 0.08 mg/ml of BSH, respectively. BSH was decanted at the necessary amounts according to the total volume of the medium, in which the compound was thoroughly dissolved by simple agitation just prior to cell treatment. Boron cellular conditioning started 7 hrs prior to irradiation: the cell growth medium was aspirated and replaced with 5 ml of BSH-containing medium. Ordinary BSH-free growth medium was replaced into flasks that were used as controls. Just before irradiation, flasks were completely filled with the respective media (with or without BSH) to prevent cells from drying since flasks are irradiated standing vertically in front of the beam.

### p + 11B → 3α nuclear fusion

The p + 11B → 3α nuclear fusion reaction at low energy can be basically described as a two-step reaction due to its behaviour at the three resonant energies (0.162 MeV, 0.675 MeV and 2.64 MeV). Firstly, a proton, interacting with 11B, induces the formation of a 12C* compound nucleus formed in the 2- or 3- excited state. If the 12C* nucleus is formed in its 2- state, it will decay to the first 2+ stat of 8Be emitting one alpha-particle with l = 362. If the 12C* nucleus is formed in its 3- state, then the primary alpha particle can be emitted either with l = 1 from the decay to the first 2+ 8Be excited state, or with l = 3 from the decay to the 0 + 8Be ground state. In either case, the remaining 8Be (2+ or 0+) nucleus immediately decays into two secondary alpha particles with l′ = 2. Alpha particles emitted in the first stage present a well-defined energy distribution and are commonly referred to as α0 and α1 if the 8Be 2+ or the 0+ states are populated, respectively. Few authors62,63 report that a very unlikely fourth channel, characterized by a maximum cross section of 10 μb in the 2.0–2.7 MeV energy range, can also be activated. In this case the 12C* directly breaks into three α particles skipping the intermediate 8Be stage, which show a continuous energy distribution.

Figure 8 reports some of the available experimental data62,63 for the total production cross section of the p + 11B → 3α reaction as function of the mass centre energy and for the α1 channel. For low energies (0.1–5 MeV) the reaction cross sections become significantly high, thus maximising the alpha particle production around the proton Bragg peak region, an advantageous feature for the alternative protontherapy approach proposed in this work.

In the case of measurement of clonogenic survival along the proton SOBP, appropriate stacks of PMMA degraders were realised to achieve varying depths along the dose-depth profile using the same setup as described in Chaudray et al.14. Low-LET reference irradiations were carried out at Physics Department, University of Naples Federico II, employing a 250 kVp radiogen x-ray STABILIPAN machine (Siemens), with 1-mm Cu filter and a dose rate of about 1.2 Gy min−1.

### Measurement of cell death

Radiation-induced cell death was assessed by means of the clonogenic test, the gold standard for measuring cellular radiosensitivity. According to this assay, a cell survives irradiation if it retains its proliferative potential and it is thus capable of forming a colony composed of at least 50 cells. After irradiation, the medium was discarded from the flasks, and DU145 cells were detached, counted by haemocytometer and re-plated at opportune densities. They were then allowed to grow for colony formation in BSH-free medium. Four replicates for each dose were used for statistical data robustness. Clones were fixed and stained by crystal violet after 10 days. Surviving fractions (SF) are obtained by dividing the number of clones by the number of cells seeded at a given dose D, normalized by the plating efficiency (PE), that is the “surviving” of cells in the absence of radiation according to the expression SFDoseD = [Number of clones/number of cells]DoseD/(PE). Experimental data were fitted to the linear-quadratic equation that best describes low-LET radiation induced cell death SF = exp (-α*D-β*D2).

### Chromosomes aberration analysis

After irradiation, MCF-10A cells were kept in BSH-free medium for up to 36 h. Genotoxic action of radiation was studied by scoring structural aberrations in chemically induced interphase chromosomes according to the Premature Chromosome Condensation (PCC) technique. Cells were incubated for 30 min with calyculin A (50 ng/mL, Sigma-Aldrich) for PCC induction as elsewhere described67. To collect PCC spreads, cells were trypsinized, centrifuged at 300g for 8 min, then the pellet was resuspended for 25 min in hypotonic solution (75 mM KCl at 37 °C), and fixed on ice in freshly prepared Carnoy solution (3:1 v/v methanol/acetic acid). Spreads were then dropped on pre-warmed (42 °C) wet slides and air-dried at room temperature. Conventional Fluorescence In Situ Hybridization (FISH) painting was conducted by using whole-chromosome fluorescence-labelled DNA painting probes directed to chromosomes 1 and 2 following the manufacturer’s recommendations (MetaSystems, Germany). Denaturation (72 °C for 3 min) followed by hybridization (37 °C overnight) of slides was performed using a hand-free HYBrite chamber system. Unlabeled chromosomes were counterstained with 12 ml 4, 6-diamidino-2-phenylindole (DAPI) staining. For m-FISH, the 24XCyte probe by MetaSystems was applied to chromosomes harvested as above described. The labelling kit contains five fluorochromes:

• CyTM5 - Cyanine 5, fluorescing in the red region (649 nm excitation, 670 nm emission);

• DEAC (DiEthylAmino-Coumarin) - λex = 409 nm, λem = 473 nm;

• FITC (Fluorescein IsoThioCyanate) - λex = 495 nm, λem = 525 nm;

• Spectrum OrangeTM - λex = 554 nm, λem = 587 nm;

• Texas Red® - λex ~ 596 nm, λem ~ 620 nm.

Software ISIS® imaging system (MetaSystems) attributes a false color pattern depending on overlap signals intensity, according to 24XCyte labeling scheme shown below (Table 3).

As per manufacturer’s directions, chromosomes and probe were denaturated by sequential treatment by 2X Saline-Sodium Citrate (SSC) solution at 70 °C for 30 min, followed by room temperature (RT) bathing in 0.1x SSC for 1 min, by RT rinse in 0.07 NaOH for 1 min, 4 °C wash in 0.1X and 2X SSC for 1 min each. Final step was sequential washing in ethanol series (70%, 95% and 100%). While slides air-dried, probe was denaturated by incubating at 75 °C incubation in a water bath for 5 min, ice-cold cooling for 30 min and incubation at 37 °C for 30 min. Denatured probe was then applied to the slide (12 μl for a 24 × 24 mm2 coverslip). Hybridization was thus carried out for 48 h using the above-mentioned HYBrite chamber. After post-hybridization washing (0.4X SSC, pH 7.0–7.5, at 72 °C; RT 2X SSC, pH 7.0–7.5, containing 0.05% Tween20®), DAPI/antifade (250 ng/ml) counterstaining was applied.

For conventional FISH scoring, slides were viewed with an epi-fluorescence microscope connected to a computer-controlled system (Metafer 4 software, MetaSystems), for automated slide scanning and three-color image acquisition. Chromosome analysis was carried out on stored images. Scoring was conducted blind by the same scorer. Not less than 500 chromosome spreads for each dose were scored (at least 1,500 for nonirradiated controls). Karyotype reconstruction and analysis was manually carried out using an Axio Imager M1 fluorescence microscope (Zeiss) with the help of the ISIS software for image processing. At least 200 chromosome spreads were analyzed for each experimental point. All types of aberrations were scored separately and categorized as simple exchanges (i.e. translocations and dicentrics), either complete or incomplete, acentric fragments and complex exchanges 68. For this study’s purpose, however, data herein presented are relative to the total chromosomal exchange frequency and to the complex-type exchange frequency. Frequency of total aberration exchanges was fitted to the equation Y = Y0+α*D+βD2.

### Statistical analysis

For analysis of the dose – response relationships for cell killing and chromosome aberration frequency, curve fitting was performed by nonlinear least square minimization (Marquardt’s algorithm) using SigmaPlot 12.5 software (SPSS, USA). Poisson statistics was assumed to derive standard errors on aberration frequencies. Experimental surviving fraction data in clonogenic assays are affected by several sources of errors, such as those associated with cell counts and cell dilutions, which are not taken into account by simple calculations of the standard error affecting colony counting. A more precise approach is needed to determine the experimental error on the plating efficiency PE as above defined and here recalled for convenience:

$$PE=(\frac{{\bar{X}}_{colonies}}{{\bar{X}}_{cells}})|0\,Gy$$
(1)

This quantity is the ratio between two mean values, i.e. the mean counted colony number and the mean number of cells seeded, each with its standard error SE: SEcolonies and SEcells. Therefore, according to the standard formula on error propagation, the standard error for plating efficiency, i.e. SE (PE), can be derived as follows:

$$\begin{array}{rcl}SE(PE) & = & \sqrt{{(\frac{\partial PE}{\partial {\bar{X}}_{colonies}})}^{2}{(S{E}_{colonies})}^{2}+{(\frac{\partial PE}{\partial {\bar{X}}_{cells}})}^{2}{(S{E}_{cells})}^{2}}\,\\ & = & \sqrt{{(\frac{1}{{\bar{X}}_{cells}})}^{2}{(S{E}_{colonies})}^{2}+{(-\frac{{\bar{X}}_{colonies}}{{{\bar{X}}_{cells}}^{2}})}^{2}{(S{E}_{cells})}^{2}}\end{array}$$
(2)

Recalling the definition of Surviving Fraction at a given dose D:

$$S{F}_{D}=(\frac{{\bar{X}}_{colonies}}{{\bar{X}}_{cells}})/PE$$
(3)

In the interest of simplicity, it can be assumed that the mean number of cells seeded that appears in the above formula is devoid of error, which is reasonable since cell counting error is taken care of in the SE (PE). This means treating $${\bar{X}}_{cells}$$ as a constant; hence we can define $$\frac{{\bar{X}}_{colonies}}{{\bar{X}}_{cells}}$$ as SF, with its error being (SEcolonies)/$$(\,{\bar{X}}_{cells})$$.Hence, SE(SFD) can be determined as follows:

$$SE(S{F}_{D})=\,\sqrt{{(\frac{1}{PE})}^{2}{(\frac{S{E}_{colonies}}{{\bar{X}}_{cells}})}^{2}+{(-\frac{SF}{{(PE)}^{2}})}^{2}{(SE(PE))}^{2}}$$
(4)

In these calculations, we assumed that observed CV is always greater than Poisson CV on all counts, of either colonies or cells; wherever this was no the case, we corrected the experimental SE by multiplying the mean (of cell or colony counts) by the Poisson CV.Error on calculated DMF at 10% survival (SF) level defined as:

$$DM{F}_{10}=\,(\frac{{D}_{noBSH}}{{D}_{BSH}})|SF=0.1\,$$
(5)

was derived by using error propagation as given by:

$$\begin{array}{rcl}\sigma DM{F}_{10} & = & \sqrt{{(\frac{\partial DM{F}_{10}}{\partial {D}_{noBSH}})}^{2}{({\sigma }_{{D}_{noBSH}})}^{2}+{(\frac{\partial DM{F}_{10}}{\partial {D}_{BSH}})}^{2}{({\sigma }_{{D}_{BSH}})}^{2}}\\ & = & \sigma DM{F}_{10}=DM{F}_{10}\,\sqrt{{(\frac{\sigma {D}_{noBSH}}{{D}_{noBSH}})}^{2}+{(\frac{\sigma {D}_{BSH}}{{D}_{BSH}})}^{2}\,}\end{array}$$
(6)

Dose uncertainties were derived using error propagation from the linear-quadratic equation SF = exp (−α*D-β*D2), which in its most general formulation reads as:

$${\sigma }_{D}=\,\sqrt{{(\frac{\partial D}{\partial \alpha })}^{2}{\sigma }_{\alpha }^{2}+{(\frac{\partial D}{\partial \beta })}^{2}{\sigma }_{\beta }^{2}}$$
(7)

Rigorously, in formula 7 there is also the covariance of the parameters α and β, which, for clonogenic survival curves, is negative as they are weakly anti-correlated, hence, this term is neglected to avoid underestimation of the error, with the partial derivatives of the dose with respect to α and β being

$$\frac{\partial D}{\partial \alpha }=\,-\frac{D}{\alpha +2\beta D}$$
(8)
$$\frac{\partial D}{\partial \beta }=-\frac{{D}^{2}}{\alpha +2\beta D}$$
(9)

## References

1. 1.

Nuclear Physics European Collaboration Committee (NuPECC), Nuclear Physics for Medicine, NuPECC Report, European Science Foundation (2014)

2. 2.

Particle Therapy Co-Operative Group. Particle Therapy Centers. Available at: http://www.ptcog.ch/ (last accessed on line August 2016).

3. 3.

Wilson, R. R. Radiological use of fast protons. Radiology 47, 487–491 (1946).

4. 4.

Bragg, W. & Kleemann, R. On the α-particles of radium and their loss of range in passing through various atoms and molecules. Phil. Mag. 10, 318–340 (1905).

5. 5.

Loeffler, J. S. & Durante, M. Charged particle therapy–optimization, challenges and future directions. Nat. Rev. Clin. Oncol. 10, 411–424 (2013).

6. 6.

Uhl, M., Herfarth, K. & Debus, J. Comparing the use of protons and carbon ions for treatment. Cancer J. 20, 433–439 (2014).

7. 7.

Verma, V. et al. Cost-comparativeness of proton versus photon therapy. Chin. Clin Oncol. https://doi.org/10.21037/cco.2016.06.03. (2016). [Epub ahead of print]

8. 8.

Tommasino, F. & Durante, M. Proton radiobiology. Cancers 12, 7353–7381 (2015).

9. 9.

Doyen, J., Falk, A. T., Floquet, V., Hérault, J. & Hannoun-Lévi, J. M. Proton beams in cancer treatments: Clinical outcomes and dosimetric comparisons with photon therapy. Cancer Treat. Rev. 43, 104–112 (2016).

10. 10.

Hall, E. J. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int. J. Radiat. Oncol. Biol. Phys. 65, 1–7 (2006).

11. 11.

Kraft, G. The radiobiological and physical basis of radiotherapy with protons and heavier ions. Strahlenther. Onkol. 166, 10–13 (1990).

12. 12.

International Commission on Radiation Units and Measurements (ICRU). Prescribing, Recording, and Reporting Proton-Beam Therapy (Report 78), J ICRU 7, Oxford University Press, Oxford (2007).

13. 13.

Belli, M. et al. Inactivation of human normal and tumour cells irradiated with low energy protons. Int.J. Radiat. Biol. 76, 831–839 (2000).

14. 14.

Chaudhary, P. et al. Relative biological effectiveness variation along monoenergetic and modulated Bragg peaks of a 62-MeV therapeutic proton beam: a preclinical assessment. Int. J. Radiat. Oncol. Biol. Phys. 90, 27–35 (2014).

15. 15.

Paganetti, H. Relative biological effectiveness (RBE) values for proton beam therapy. Variations as a function of biological endpoint, dose, and linear energy transfer. Phys. Med. Biol. 59, R419–472 (2014).

16. 16.

Girdhani, S., Sachs, R. & Hlatky, L. Biological effects of proton radiation: What we know and don’t know. Radiat. Res. 179, 257–272 (2013).

17. 17.

Durante, M. New challenges in high-energy particle radiobiology. Br. J. Radiol. 87, 20130626 (2014).

18. 18.

Schulz-Ertner, D. & Tsujii, H. Particle radiation therapy using proton and heavier ion beams. J. Clin. Oncol. 25, 953–964 (2007).

19. 19.

Amaldi, U. & Kraft, G. Radiotherapy with beams of carbon ions. Rep. Prog. Phys. 68, 1861–1882 (2005).

20. 20.

Suzuki, M., Kase, Y., Yamaguchi, H., Kanai, T. & Ando, K. Relative biological effectiveness for cell-killing effect on various human cell lines irradiated with heavy-ion medical accelerator in Chiba (HIMAC) carbon-ion beams. Int. J. Radiat. Oncol. Biol. Phys. 48, 241–250 (2000).

21. 21.

Facoetti, A. et al. In vivo radiobiological assessment of the new clinical carbon ion beam at CNAO. Radiat. Prot. Dosim. 166, 379–382 (2015).

22. 22.

Ward, J. F. The complexity of DNA damage: relevance to biological consequences. Int. J. Radiat. Biol. 66, 427–432 (1994).

23. 23.

Goodhead, D. T. Initial events in the cellular effects of ionizing radiations: clustered damage in DNA. Int. J. Radiat. Biol. 65, 7–17 (1994).

24. 24.

Hada, M. & Sutherland, B. M. Spectrum of complex DNA damages depends on the incident radiation. Radiat. Res. 165, 223–230 (2006).

25. 25.

Gustafsson, A. S., Hartman, T. & Stenerlöw, B. Formation and repair of clustered damaged DNA sites in high LET irradiated cells. Int. J. Radiat. Biol. 91, 820–826 (2015).

26. 26.

Raju, M. R. et al. A heavy particle comparative study. Part III: OER and RBE. Br. J. Radiol. 51, 712–719 (1978).

27. 27.

Held, K. D. et al. Effects of Charged Particles on Human Tumor Cells. Front. Oncol. 12, 6–23 (2016).

28. 28.

Ogata, T. et al. Carbon ion irradiation suppresses metastatic potential of human non-small cell lung cancer A549 cells through the phosphatidylinositol-3-kinase/Akt signaling pathway. J. Radiat. Res. 52, 374–379 (2011).

29. 29.

Fujita, M. et al. Carbon-ion irradiation suppresses migration and invasiveness of human pancreatic carcinoma cells MIAPaCa-2 via Rac1 and RhoA Degradation. Int. J. Radiat. Oncol.Biol. Phys. 93, 173–180 (2015).

30. 30.

Fujita, M. et al. Carbon-ion radiation enhances migration ability and invasiveness of the pancreatic cancer cell, PANC-1. in vitro. 103, 677–683 (2012).

31. 31.

Lin, Y., McMahon, S. J., Paganetti, H. & Schuemann, J. Biological modeling of gold nanoparticle enhancers radiotherapy for proton therapy. Phys. Med. Biol. 60, 4149–4168 (2015).

32. 32.

Do-Kun, Y., Joo-Young, J. & Tae, S. S. Application of proton boron fusion reaction to radiation therapy: A Monte Carlo simulation study. Appl. Phys. Lett. 105, 223507 (2014).

33. 33.

Oliphant, M. & Rutheford, L. Experiments on the transmutation of elements by protons. Proc. R. Soc. Lond. A 141, 259–272 (1933).

34. 34.

Dee, P. I. & Gilbert, C. W. The disintegration of Boron into three α-particles. Proc. R. Soc. Lond. A 154, 279 (1936).

35. 35.

Barth, R. F. From the laboratory to the clinic: How translational studies in animals have lead to clinical advances in boron neutron capture therapy. Appl. Radiat. Isot. 106, 22–28 (2015).

36. 36.

Doi, A., Kawabata, S., Lida, K., Yokoyama, K. & Kajimoto, Y. et al. Tumour-specific targeting of sodium borocaptate (BSH) to malignant glioma by transferrin-PEG liposomes: a modality for boron neutron capture therapy. Neurooncol. 87, 287–294 (2008).

37. 37.

Anderson, R. M. et al. Complex chromosome aberrations in peripheral blood lymphocytes as a potential biomarker of exposure to high-LET alpha particles. Int. J. Radiat. Biol. 76, 31–42 (2000).

38. 38.

Spraker, M. C. et al. The 11B(p, α)8Be → α + α and the 11B(α, α)11B reactions at energies below 5.4 MeV. J. Fusion Energ. 31, 357–367 (2012).

39. 39.

Sikora, M. H. & Weller, H. R. A. new evaluation of the 11B(p, α)αα reaction rates. J. Fusion. Energ. 35, 538–543 (2016).

40. 40.

Stave, S. et al. H.R., Understanding the 11B(p, α)αα reaction at the 0.675 MeV resonance. Phys. Lett. B 696, 26–29 (2011).

41. 41.

Rostoker, N., Binderbauer, M. W. & Monkhorst, H. J. Colliding beam fusion reactor. Science 278, 1419–1422 (1997).

42. 42.

Picciotto, A. et al. Boron-proton nuclear-fusion enhancement induced in boron-doped silicon targets by low-contrast pulsed laser. Phys. Rev. X 4, 031030 (2014).

43. 43.

Giuffrida, L., Margarone, D., Cirrone, G.A.P. & Picciotto, A. Prompt gamma ray diagnostics and enhanced hadron-therapy using neutron-free nuclear reactions, arXiv:1608.06778 AIP Advances 6, 105204 (2016)

44. 44.

Petringa, G. et al. Study of gamma-ray emission by proton beam interaction with injected Boron atoms for future medical imaging applications, Journal of Instrumentation 12(03) (2017)

45. 45.

Petringa, G. et al. Prompt gamma-ray emission for future imaging applications in proton-boron fusion therapy. Journal of Instrumentation 12(03), C03059–C03059 (2017).

46. 46.

Barth, R. F., Coderre, J. A., Vicente, M. G. & Blue, T. E. Boron neutron capture therapy of cancer: status and future prospects. Clin. Cancer Res. 11, 3987–4002 (2005).

47. 47.

Schwint, A. E. & Trivillin, V. A. 'Close-to-ideal' tumor boron targeting for boron neutron capture therapy is possible with 'less-than-ideal' boron carriers approved for use in humans. Ther Deliv. 6, 269–272 (2015).

48. 48.

Yasui, L. et al. Boron neutron capture in prostate cancer cells. Appl. Radiat. Isot. 70, 6–12 (2012).

49. 49.

Savage, J. R. & Tucker, J. D. Nomenclature systems for FISH-painted chromosome aberrations. Mutat. Res. 366, 153–161 (1996).

50. 50.

Bedford, J. S., Mitchell, J. B., Griggs, H. G. & Bender, M. A. Radiation-Induced Cellular Reproductive Death and Chromosome Aberrations. Radiat. Res. 76, 573–586 (1978).

51. 51.

Brenner, D. J. & Sachs, R. K. Chromosomal “fingerprints” of prior exposure to densely ionizing radiation. Radiat. Res. 140, 134–142 (1994).

52. 52.

George, K. et al. Biological effectiveness of accelerated particles for the induction of chromosome damage measured in metaphase and interphase human lymphocytes. Radiat. Res. 160, 425–435 (2003).

53. 53.

Barth, R. F. et al. Current status of Boron neutron capture therapy for high grade gliomas and recurrent head and neck cancer. Radiation Oncology 7, 146, https://doi.org/10.1186/1748-717X-7-146 (2012).

54. 54.

Kankaanranta, L., Seppala, T., Koivunoro, H. & Saarilahti, K. et al. Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: final analysis of a Phase I/II trial. Int. Jour.of Rad. Onc. Biol. Phys. 82, e67–e75 (2012).

55. 55.

Polf, J. C. et al. Enhanced relative biological effectiveness of proton radiotherapy in tumor cells with internalized gold nanoparticles. Appl. Phys. Lett. 98, 193702 (2011).

56. 56.

Schmid, T. E. et al. The effectiveness of the high-LET radiations from the boron neutron capture [10B(n,a)7Li] reaction determined for induction of chromosome aberrations and apoptosis in lymphocytes of human blood samples. Radiat. Environ. Biophys. 54, 91–102 (2015).

57. 57.

Barquinero, J. F., Stephan, G. & Schmid, E. Effect of americium-241 -particles on the dose–response of chromosome aberrations in human lymphocytes analysed by fluorescence in situ hybridization. Int. J. Radiat. Biol. 80, 155–164 (2004).

58. 58.

Schwint, A. E. & Trivillin, V. A. ’Close-to-ideal’ tumor boron targeting for boron neutron capture therapy is possible with ‘less-than-ideal’ boron carriers. Ther. Deliv. 6, 269–272 (2015).

59. 59.

Shin, H.-B., Yoon, D. K., Jung, J. Y., Kim, M. S. & Suh, T. S. Prompt gamma ray imaging for verification of proton boron fusion therapy: A Monte Carlo study. Phys. Med. 32, 1271–1275 (2016).

60. 60.

Kumar, C. et al. Relevance of radiobiological concepts in radionuclide therapy of cancer. Int. J. Radiat. Biol. 92, 173–186 (2016).

61. 61.

Debnath, J., Muthuswamy, S. K. & Brugge, J. S. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30, 256–268 (2003).

62. 62.

Becker, H. W., Rolfs, C. & Trautvetter, H. P. Low-energy cross sections for 11B(p,3α), Z. Phys. A Atomic Nuclei 327, 341–355 (1987).

63. 63.

Segel, R. E., Hanna, S. S. & Allas, R. G. States in C12 between 16.4 and 19.6 MeV. Phys. Rev. 139, 818–830 (1965).

64. 64.

Cuttone, G. et al. Use of 62 MeV proton beam for medical applications at INFN-LNS: CATANA project. Physica Medica 17, 23–25 (2001).

65. 65.

Cirrone, G. A. P. et al. A 62 MeV proton beam for the treatment of ocular melanoma at Laboratori Nazionali del Sud-INFN. IEEE Trans. Nucl. Sci. 51, 860–865 (2004).

66. 66.

International Atomic Energy Agency, TRS-398, Absorbed dose determination in external beam radiotherapy - An international code of practice for dosimetry based on standards of absorbed dose to water (V.12), http://www-naweb.iaea.org/nahu/DMRP/documents/CoP_V12_2006-06-05.pdf (2006).

67. 67.

Durante, M., Furusawa, Y. & Gotoh, E. A simple method for simultaneous interphase-metaphase chromosome analysis in biodosimetry. Int. J. Radiat. Biol. 74, 457–462 (1998).

68. 68.

Manti, L. et al. Measurements of metaphase and interphase chromosome aberrations transmitted through early cell replication rounds in human lymphocytes exposed to low-LET protons and high-LET 12C ions. Mutat. Res. 596, 151–165 (2006).

## Acknowledgements

This research was sponsored by the INFN (Italian Institute for Nuclear Physics), by the project ELI - Extreme Light Infrastructure – Phase 2 (CZ.02.1.01/0.0/0.0/15_008/0000162) through the European Regional Development Fund and by the Czech Science Foundation (project No. 15-02964S). The authors gratefully acknowledge Rachael Jack for the support provided to improve the readability of the manuscript and the Director and Accelerators technical staff of INFN-LNS for providing the extra beam for the experiments. Authors also wish to thank Prof Claudio Spitaleri (University of Catania and INFN-LNS) and Dr Marco La Cognata (INFN-LNS) for the help and suggestions in the study and interpretation of the p-11B reaction.

## Author information

Authors

### Contributions

Dr G.A.P. Cirrone contributed to the conceptual idea of dose enhancement, proposed the biological measure, organized the experimental measures and followed all the dosimetric procedures; he contributed to the Monte Carlo simulations and to the analytical calculations; he organized the manuscript preparation and finalization. Dr L. Manti designed and carried out the radiobiological experiment, analyzed data and contributed to the discussion of the results and the writing of the manuscript. Dr D. Margarone contributed to the conceptual idea of dose enhancement and prompt gamma ray generation, experiment participation and manuscript preparation. Dr. G. Petringa performed the Monte Carlo simulations of the set-up analytical estimations; she also participated to the preparation of the experimental set-up and irradiation and contributed to the preparation and revision of the second version of the manuscript. Dr L. Giuffrida contributed in the conceptual idea, calculation of dose enhancement and consideration on prompt gamma ray generation; he prepared the Fig. 1 describing the studied effect. Dr. A. Minopoli carried out hybridization, data acquisition and analysis for m-FISH investigation of chromosomal aberration. Dr A. Picciotto supported the idea of fusion reaction for the described application, participated to the experiment and into the manuscript preparation and revision. Dr G. Russo and Dr F. Cammarata followed and contributed to the radiobiological experiments also contributing to the clonogenic analysis; Dr P. Pisciotta carried out relative and absolute proton beam dosimetry and was in charge of cell positioning during irradiations; Dr F.M. Perozziello contributed to the experimental work on cell survival and data analysis. Dr F. Romano contributed to the dosimetric set-up in one of the experimental irradiation; Dr V. Marchese, Dr V. Scuderi and Dr G. Milluzzo contributed to the experimental set-up preparation for cells irradiation; Dr G. Cuttone and G. Korn contributed to the conceptual idea of dose enhancement, to the manuscript preparation and generally supported the whole idea and project.

### Corresponding author

Correspondence to G. A. P. Cirrone.

## Ethics declarations

### Competing Interests

The main author, on behalf of whole collaboration, declare that Dr GAP Cirrone, L Giuffrida, D Margarone, A Picciotto submitted an European patent on the use of 11B for cancer therapy and diagnostic. The other authors have not competing financial interests related to this work.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Rights and permissions

Reprints and Permissions

Cirrone, G.A.P., Manti, L., Margarone, D. et al. First experimental proof of Proton Boron Capture Therapy (PBCT) to enhance protontherapy effectiveness. Sci Rep 8, 1141 (2018). https://doi.org/10.1038/s41598-018-19258-5

• Accepted:

• Published:

• ### Studies on the Exposure of Gadolinium Containing Nanoparticles with Monochromatic X-rays Drive Advances in Radiation Therapy

• Fuyuhiko Tamanoi
• , Kotaro Matsumoto
• , Tan Le Hoang Doan
• , Ayumi Shiro
•  & Hiroyuki Saitoh

Nanomaterials (2020)

• ### Enhancement of Radiation Effectiveness in Proton Therapy: Comparison Between Fusion and Fission Methods and Further Approaches

• Farshid Tabbakh
•  & Narayan S. Hosmane

Scientific Reports (2020)

• ### A theoretical model for the cross section of the proton-boron fusion nuclear reaction

• Federico Alejandro Geser
•  & Mauro Valente

• ### The potential role of borophene as a radiosensitizer in boron neutron capture therapy (BNCT) and particle therapy (PT)

• Pengyuan Qi
• , Qianyuan Chen
• , Dong Tu
• , Songhuan Yao
• , Yupeng Zhang
• , Jike Wang
• , Conghua Xie
• , Chunxu Pan
•  & Hao Peng

Biomaterials Science (2020)

• ### A Model for Estimating Dose-Rate Effects on Cell-Killing of Human Melanoma after Boron Neutron Capture Therapy

• Yusuke Matsuya
• , Hisanori Fukunaga
• , Motoko Omura
•  & Hiroyuki Date

Cells (2020)